Is GLP-1 Covered by Insurance? The 2026 Navigation Guide

Quick Answer

Whether you can get a GLP-1 covered by insurance in 2026 depends more on your coverage system than on the drug.

  • Firms with 200+ workers: 16% to 43% cover it primarily for weight loss (KFF).
  • Medicare’s Bridge gives eligible enrollees certain GLP-1s for a $50 copay from July 2026.
  • Under 1% of denied HealthCare.gov claims were appealed in 2024.
Organizing the paperwork that gets a GLP-1 covered by insurance in 2026.

Getting a GLP-1 covered by insurance works differently in every country, and the four systems below are the United States ones. Australian readers should check the PBS listing and their private cover; UK readers should check NHS and NICE guidance.

Two people, same medication, same dose. One pays a small copay through work. The other gets a flat no and a list price above $1,300. The difference is rarely medical. It comes down to which coverage system you sit in: an employer plan, an ACA marketplace plan, Medicare, or Medicaid, plus a self-pay market that rewrote its prices this year.

Coverage moved in both directions in 2026. More people lost commercial coverage for Zepbound while Medicare opened to these drugs for the first time, and California’s Medicaid program stopped covering them for weight loss alone in January. Meanwhile manufacturer-direct prices fell far enough that paying cash stopped being unthinkable. The map below shows where each system stands, what decides your answer, and your first move in each one.

Is GLP-1 covered by insurance for weight loss in 2026?

Sometimes, and your plan type predicts the answer better than anything about you or your prescription. Plans that won’t cover the drugs for weight loss alone may make exceptions for other conditions, NPR reports. Even for Type 2 diabetes, getting a GLP-1 covered by insurance usually comes with added restrictions, 78% of the time for Mounjaro and over 89% for Ozempic, GoodRx finds. Weight loss is where plans draw the line, because the drugs are expensive for plans and the employers that pay for them.

The 2026 coverage count: as of July 2026, 27 million people with commercial insurance have no Wegovy coverage, 114 million have none for Zepbound, and nearly 13 million have no coverage for any weight-loss GLP-1, according to GoodRx’s coverage tracker, read on October 18, 2026. The tracker is revised through the year, and the company behind it sells prescription discounts, so the numbers are both dated and interested. Where coverage does exist, it comes with homework: 88% of people who have it still have to meet extra requirements such as prior authorization.

Those are national numbers, and national numbers don’t fill prescriptions. Your answer lives inside one of four systems, and each one runs on different rules.

Coverage system Where it stands in 2026 What decides your answer Your first move
Employer plan The biggest system and the most uneven: 16% of firms with 200 to 999 workers cover weight-loss GLP-1s, 43% at 5,000 or more (KFF, 2025). Your employer’s plan design. The insurer’s name on the card decides nothing. Pull the formulary and check the drug’s tier: how to check your coverage.
ACA marketplace Coverage for weight loss is limited, and HealthCare.gov insurers denied 19% of in-network claims in 2024 (KFF). Your plan’s formulary and its exception process. Check the formulary first; if you’re denied, appeal it with the GLP-1 insurance appeal guide and its sample letter.
Medicare Open for the first time: the GLP-1 Bridge gives eligible Part D enrollees a $50 monthly copay from July 1, 2026 to December 31, 2027 (CMS). Bridge eligibility criteria plus Part D enrollment. Check the Bridge eligibility rules in the Medicare GLP-1 coverage guide before you fill anything.
Medicaid State by state, and tightening: 13 state programs covered weight-loss GLP-1s under fee-for-service in January 2026 (KFF), and Medi-Cal ended its coverage for adults on January 1 (DHCS). Your state’s covered drug list and your diagnosis code. Check your state’s Medicaid drug list; diabetes and some other diagnoses still qualify.
Paying cash Manufacturer-direct prices start at $149 to $299 a month, against list prices of $1,028 to $1,349 (TrumpRx). Which drug and which channel; the gap between routes runs to hundreds of dollars. Compare the self-pay routes before you pay list price.

Treat the table as the pattern, not your plan. Individual plans differ inside every row, so your own plan documents outrank any general rule on this page.

How do I know if my insurance will cover a GLP-1?

Your plan’s formulary answers the question in about ten minutes. That document lists every drug the plan covers and the conditions attached to each, and you can pull it yourself from the plan website or member portal without calling anyone.

The name on your insurance card tells you close to nothing here. Employer plans buy their drug benefit separately, and two people with the same insurer logo can get opposite answers because one employer bought weight-loss coverage and the other declined it. One split inside that matters more than the logo on the card: if your employer self-funds, it pays the claims itself and the insurer only administers them, which puts the real decision with your benefits department. Fully-insured plans work the other way and pick up state rules that self-funded plans do not. Forum threads on coverage keep landing on one concrete step: ask HR for the plan’s Summary Plan Description.

Company size is the strongest signal you can read from the outside: in KFF’s 2025 Employer Health Benefits Survey, 16% of firms with 200 to 999 workers covered GLP-1s primarily for weight loss, 30% of firms with 1,000 to 4,999 workers, and 43% of firms with 5,000 or more. That last figure jumped from 28% a year earlier, so the biggest employers kept adding coverage, while the overall share among firms with 200 or more workers barely moved: 19%, against 18% the year before. About a third of covering firms (34%) also require enrollees to meet with a dietitian, case manager or therapist, or join a lifestyle program, before the drug is covered.

Marketplace plans are a different animal. If you buy your own coverage on HealthCare.gov or a state exchange, coverage of GLP-1s for weight loss is limited, KFF’s January 2026 brief notes, and the claims environment is rough in general: insurers on HealthCare.gov denied 19% of in-network claims in 2024, per KFF’s analysis of federal transparency data. If the drug isn’t on your formulary, the formulary-exception process is the tool built for exactly that request, and your prescriber files it with you.

The walkthrough on how to check if your insurance covers Wegovy or Zepbound turns all of this into a step-by-step method: where the formulary hides, what the tier numbers mean, and the five questions to ask if you do end up on the phone, so you know your cost before you fill. The same logic extends past weight loss: prescriptions tied to PCOS, for example, rise or fall on the diagnosis code and the plan’s drug list.

What changed for Medicare and Medicaid in 2026?

The two government systems rewrote their rules this year, in opposite directions.

Medicare opened. Starting July 1, 2026, the Medicare GLP-1 Bridge gives eligible Part D enrollees access to certain GLP-1 drugs for a flat $50 monthly copay, and it runs through December 31, 2027. It’s a short-term demonstration that operates outside the normal Part D benefit, which cuts both ways: your Part D plan does not have to opt in for you to use it, but the Part D deductible does not apply, no part of the $50 counts toward your true out-of-pocket total, and there is no low-income subsidy on it.

Eligibility has real teeth, with BMI thresholds, condition requirements, and a short list of qualifying products. It is also for weight management only. CMS tells prescribers that Type 2 diabetes, moderate to severe obstructive sleep apnea and noncirrhotic MASH (a fatty liver disease with moderate to advanced liver scarring, short of cirrhosis) are Part D indications, so anyone with one of those diagnoses is eligible for GLP-1s through their Part D plan, and therefore not for the Bridge, even if they meet its criteria.

A prescription to cut the risk of major heart events goes to the Part D plan too. The Medicare GLP-1 coverage guide walks through who qualifies, how the program’s central processor handles prior authorization, and what to do if the prior authorization comes back denied.

Medicaid moved the other way, at least in the biggest state. California’s Medi-Cal ended coverage of GLP-1s prescribed for weight loss alone on January 1, 2026 for members 21 and older, and previously approved prior authorizations ended on December 31, 2025. California is not alone: KFF counted 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service as of January 2026, after California, New Hampshire, Pennsylvania and South Carolina dropped that coverage.

The exceptions map to diagnoses. States choose whether to cover weight-loss drugs, but Medicaid must cover GLP-1s for diabetes, Wegovy for cardiovascular disease and Zepbound for moderate to severe sleep apnea in adults with obesity, KFF explains. In Medi-Cal, Type 2 diabetes coverage continues with a diagnosis code, and so does Wegovy for the liver condition MASH; Wegovy for cardiovascular disease and Zepbound for obstructive sleep apnea go through a prior authorization request. Every state sets its own drug list, so a Medicaid answer starts with your state’s list.

A termination letter isn’t the end of the process. Medi-Cal members generally have 90 days to request a State Hearing. Asking within 10 days of the notice could also keep the drug coming while the hearing was decided, but only for members taking it on or before January 1, 2026, and only until the earlier of the decision or the end of their current authorization. Those authorizations ended with 2025.

Why won’t insurance cover GLP-1 medications?

Cost, multiplied by how many people qualify. A medication priced over $1,000 a month at list, prescribed to a meaningful share of a workforce, taken indefinitely, is a line item no benefits manager can ignore. In the same KFF survey, 66% of covering firms with 5,000 or more workers said GLP-1 coverage had a significant impact on their prescription drug spending, and 59% said use ran higher than they expected.

The result has been a pullback, though not in every direction at once: the same GoodRx read shows 1.6 million people gaining some form of commercial Wegovy coverage in 2026, against 17 million more with no commercial Zepbound coverage than a year earlier. One pharmacy benefit manager’s formulary reaches a lot of people, and CVS Caremark says it has about 88 million plan members. It removed Zepbound from its standard formulary in 2025, GoodRx notes, and announced in May 2026 that it would add Zepbound back to its commercial formularies as a preferred option from October 1, 2026.

Plan sponsors using those formularies still choose whether to cover weight-loss GLP-1s at all, so the reversal is not coverage by itself. If Caremark switched you off Zepbound, the October change is worth a call to your plan before you pay cash for another month. And among firms with 200 or more workers that don’t cover the drugs today, 67% told KFF they are not likely to start within the next year.

A distinction hiding in that pullback does a lot of work. A denial is a decision made about your claim, and decisions can be contested. An exclusion means your plan never bought weight-loss drug coverage in the first place, and no appeal letter changes what a plan doesn’t contain. So read the letter. Which one you’re holding decides your next move.

The longer arc points somewhere better. Dr. Caleb Alexander, professor of epidemiology and medicine at the Johns Hopkins Bloomberg School of Public Health, told NPR he thinks obesity drugs will eventually become affordable. Statins were once expensive and hard to get covered, he notes, and now they’re generic and often cost a few dollars. “I know it’s hard to imagine,” he said. “But there will come a day when we no longer see these access barriers for GLP-1s.”

What can I do if my insurance won’t cover a GLP-1?

Match the move to what happened, because a denial, an exclusion, and a mid-year change each have a different playbook.

If you were denied, appeal. Fewer than 1% of denied marketplace claims were appealed in 2024, per KFF. Almost nobody pushes back, which means the system’s default assumption is that you won’t. When people do appeal, insurers uphold their own decision about two thirds of the time. Those figures cover HealthCare.gov claims for care already given and leave out denied prior authorization requests, so read them as a sign of how rarely people push back rather than as your odds. The guide to writing a GLP-1 appeal letter gives you the denial-reason table, the federal deadlines, and a fill-in template built around medical necessity.

If your plan excludes weight-loss drugs outright, the stronger path usually runs through a different diagnosis. Zepbound’s approval for obstructive sleep apnea can turn an excluded prescription into a covered one, with its own criteria and its own paperwork, though forum threads also report plans with a blanket weight-loss exclusion denying it anyway. Zepbound for sleep apnea: insurance coverage differences covers how that route differs from the weight-loss one. The other route Dr. Alexander points to is screening with your doctor for qualifying conditions: undiagnosed diabetes, he told NPR, is the most likely way to go from not qualifying to qualifying.

If you had coverage and your employer pulled it mid-year, you have notice rights and exception routes to check first. What to do when your employer removes GLP-1 coverage mid-year walks through them, from the plan documents your administrator owes you to the formulary exception request worth filing before you pay cash.

If none of that lands, self-pay is the next stop. In November 2025 the administration announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1s for people buying direct through TrumpRx, KFF reports. If you can’t get a GLP-1 covered by insurance under any of the four systems, manufacturer-direct pricing on TrumpRx now starts at $149 a month for the Wegovy pill, $199 for the Wegovy pen or Ozempic, and $299 for Zepbound, against list prices of $1,028 to $1,349.

The Costco option needs a caveat before you plan around it. Sesame’s January 2026 update says current Costco Weight Loss enrollees can continue, billed a program fee of $179 every three months. It points other Costco members interested in weight loss to Success by Sesame, its online program. The pharmacy price is separate: Costco members with a prescription pay $349 a month for Wegovy or Ozempic injections, self-paying at Costco Pharmacy. An HSA or FSA can pay for the drugs with pretax dollars, NPR notes.

Some people instead switch to a GLP-1 their plan already covers rather than pay cash for the excluded one, and GLP-1 medications compared shows what changes between drugs if you take that route. For the full price table across every channel, including where compounded products now stand, the GLP-1 cost comparison puts the options side by side.

Which guide should you read first?

Name your situation and read the one guide written for it. Each of these assumes nothing about what you already know.

And if a denial letter is already sitting in front of you, skip the reading order and take the template. It’s the same fill-in appeal letter the denial guide builds, with the medical-necessity language and the deadlines in place.

Get the GLP-1 Appeal Letter Template

A fill-in-the-blank appeal letter built around your specific denial reason, with the medical-necessity language and deadlines already in place. You start from a finished draft, which turns the appeal into an afternoon’s work. Free, sent to your inbox.

GLP Playbook - Insurance Appeal Magnet Capture

This also adds you to my monthly roundup: what is new on the site, plus any discount codes I have that month. The codes only go out in that email.

Your template lands first, then a few helpful emails on GLP-1 coverage. Unsubscribe anytime.

References

  1. KFF, 2025 Employer Health Benefits Survey (October 2025).
  2. KFF, Claims Denials and Appeals in ACA Marketplace Plans in 2024 (March 24, 2026).
  3. KFF, Medicaid Coverage of and Spending on GLP-1s (January 16, 2026).
  4. Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge.
  5. Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge: Information for Providers, for the eligible products and the Part D indications that make a beneficiary ineligible.
  6. California DHCS, Medi-Cal Rx, Changes to GLP-1 Drug Coverage, Effective January 1, 2026.
  7. NPR, Trouble getting weight loss drugs covered by insurance? Here’s what to know (June 23, 2026).
  8. GoodRx Research, Tracking Insurance Coverage for GIP and GLP-1 Agonists (live tracker, read November 3, 2026).
  9. TrumpRx, Most-Favored-Nation prescription pricing (prices change without notice; read October 18, 2026).
  10. CVS Health, CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options (May 28, 2026).
  11. Sesame, Update to the Costco Weight Loss Program (updated January 6, 2026).

This guide is general information, not legal or insurance advice. Plans vary, so read your own plan documents and confirm rules, criteria, and deadlines with your insurer. Every source was read on October 18, 2026. The GoodRx tracker and the TrumpRx price list both change without notice, so treat their figures as read on that date.